

**BAA NIH-BARDA-NIAID-DMID-AI2007007  
Amendment #1**

**“Biodefense Vaccine Enhancement”**

Amendment No.:	1
Amendment Issue Date:	November 8, 2007
Proposal Due Date/Time: (UNCHANGED)	January 22, 2008, at 3 P.M., EST
Issued By/ Point of Contact: (UNCHANGED)	<b>Primary Point of Contact:</b>  Jordan T. Pulaski Contracting Officer Phone: 301-451-2569 Fax: 301-402-0972 E-mail: <a href="mailto:jpulaski@niaid.nih.gov">jpulaski@niaid.nih.gov</a>  <b>Secondary Point of Contact:</b>  Terry Baughman Contracting Officer Phone: 301-451-3690 Fax: 301-402-0972 E-mail: <a href="mailto:baughmat@niaid.nih.gov">baughmat@niaid.nih.gov</a>

---

Offerors must acknowledge receipt of this Amendment #1, on each copy of the proposal submitted. Failure to receive your acknowledgment of this Amendment may result in the rejection of your proposal.

The hour and date specified for receipt of proposals HAS NOT been extended.

---

**PURPOSE: This Amendment includes the following revisions:**

**1. Section H, Article H.18, second paragraph, is revised to read as follows:**

"This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Department of Health and Human Services, in conjunction with the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN....."

**2. Page 44, Section L, paragraph 2.a.11.d.1., is revised as follows:**

The reference to "programmatic balance" should be replaced with "BARDA and NIAID programmatic balance."

**3. Attachments 3, 4, 7, and 11,**

**a. Page 84, Attachment 3,** Broad Agency Announcement Description, within the fifth paragraph, the reference to "programmatic balance" should be replaced with "BARDA and NIAID programmatic balance."

**b. Page 86 Attachment 4,** Background and Introduction, the first two sentences of the fourth paragraph are revised to read as follows:

**Part B** encompasses recombinant protective antigen (rPA)-based third generation anthrax vaccine candidates. Vaccine candidates eligible for support under **Part B** shall have, at a minimum, proof of concept data that indicate the candidate vaccine possesses potential for achieving both protective immunity following the administration of 1-2 doses and long-term stability (i.e., 3 years or longer) at temperatures of at least 35°C.

**c. Page 110, Attachment 7,** Evaluation Factors for Award (Part A), within the second and fourth paragraphs, the reference to "programmatic balance" should be replaced with "BARDA and NIAID programmatic balance."

**d. Page 159, Attachment 11,** Evaluation Factors for Award (Part B), within the second and fourth paragraphs, the reference to "programmatic balance" should be replaced with "BARDA and NIAID programmatic balance."

**4. Attachment 2 – Proposal Intent Response Sheet,** is revised to correct the BAA number cited at the top of the Sheet to read NIH-BARDA-NIAID-DMID-AI2007007.

**All offerors are requested to use the corrected version attached to this Amendment.**

**PROPOSAL INTENT RESPONSE SHEET**

**BAA No.: NIH-BARDA-NIAID-DMID-AI2007007**

**RFP Title: Biodefense Vaccine Enhancement**

Please review the attached Broad Agency Announcement. Furnish the information requested below and return this page by **November 19, 2007**. Your expression of intent is not binding but will greatly assist us in planning for proposal evaluation.

☐ DO INTEND TO SUBMIT A PROPOSAL

☐ DO NOT INTEND TO SUBMIT A PROPOSAL FOR THE FOLLOWING REASONS:

**Company/Institution Name (print):** \_\_\_\_\_

**Address (print):** \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**Project Director's Name (print):** \_\_\_\_\_

**Title (print):** \_\_\_\_\_

**Signature/Date:** \_\_\_\_\_

**Telephone Number and E-mail Address (print clearly):**

\_\_\_\_\_  
\_\_\_\_\_

**\*Name of individual to whom electronic proposal instructions should be sent:**

**Name:** \_\_\_\_\_

**Title:** \_\_\_\_\_

**E-Mail Address:** \_\_\_\_\_

**Telephone Number:** \_\_\_\_\_

**Names of Collaborating Institutions and Investigators (include Subcontractors and Consultants) (print):**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

*(Continue list on a separate page if necessary)*

RETURN VIA FAX OR E-MAIL TO:

OA, DEA, NIAID, NIH

6700-B Rockledge Drive, Room 3214, MSC 7612

Bethesda, MD 20892-7612

Attn: Jordan T. Pulaski

BAA-NIH-BARDA-NIAID-DMID-AI2007007

FAX# (301) 402-0972

Email: [jpulaski@niaid.nih.gov](mailto:jpulaski@niaid.nih.gov)